Zhi Tong Cai Jing·2025-10-24 07:42Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Group 1 - The Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were originally launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [1] - The application for the change of marketing authorization holder was submitted to the National Medical Products Administration in September 2025 and has been accepted [1]